Loading clinical trials...

A Study of Glipizide to Treat High Blood Sugar in People With Pancreatic Cancer | Clinical Trials | Clareo Health

ACTIVE_NOT_RECRUITINGPHASE2

A Study of Glipizide to Treat High Blood Sugar in People With Pancreatic Cancer

Sulfonylurea Safety and Effectiveness (SUSS) for Patients With Hyperglycemia and Pancreatic Ductal Adenocarcinoma: A Pragmatic Clinical Trial and Accompanying Retrospective Revie

NCT06168812•Memorial Sloan Kettering Cancer Center

View on ClinicalTrials.gov

Summary

The purpose of this study is to find out how effective and safe glipizide is for lowering blood sugar in people with pancreatic cancer.

Eligibility

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Cohort 1
•Age ≥18 years
•Biopsy-proven PDAC
•Radiological evidence and clinical assessment that patient has active disease (local, locally advanced, or metastatic)
•Willing and able to comply with the requirements of the protocol
•Willing to use their bluetooth-enabled wifi or cellular mobile device
•Hemoglobin A1c (HbA1c) \> 7%, or fructosamine \> 287 mg/dL, or random glucose \> 180 mg/dL, or strong clinical suspicion that patient has hyperglycemia, making it reasonable to expect their mean daily glucose is ≥154 mg/dL
•Eastern Cooperative Oncology Group performance status ≤2
•BMI \<30 kg/m2
•Cohort 2a
+14 more criteria

Exclusion Criteria

•Cohort 1
•Use during the past month of any antidiabetic medication other than metformin at home (sporadic use \[fewer than 1 of 7 days during the past month\] is permitted)
•Changes in metformin dose in the past month
•History of sulfonylurea intolerance or allergy
•History of severe hypoglycemia (hypoglycemia requiring emergency medical assistance, emergency room or urgent care visit, or hospital admission)
•AST or ALT \>3 x upper limit of normal
•Glomerular filtration rate \<30 mL/min/1.73m2
•Daily chronic use of any dose of corticosteroids (as distinct from intermittent exposure to steroids as part of cyclic chemotherapy)
•Inability to wear CGM
•Cohort 2a
+3 more criteria

Locations (7)

Memorial Sloan Kettering at Basking Ridge (Limited Protocol Activities)

Basking Ridge, New Jersey, United States

Memorial Sloan Kettering Monmouth (Limited protocol activities)

Middletown, New Jersey, United States

Memorial Sloan Kettering Bergen (Limited Protocol Activities)

Montvale, New Jersey, United States

Memorial Sloan Kettering Cancer Center @ Suffolk-Commack (Limited protocol activities)

Commack, New York, United States

Memorial Sloan Kettering Westchester (Limited Protocol Activities)

Harrison, New York, United States

Memorial Sloan Kettering Cancer Center

New York, New York, United States

Memorial Sloan Kettering Nassau (Limited Protocol Activities)

Uniondale, New York, United States

Key Dates

Start Date

December 5, 2023

Primary Completion Date

December 5, 2026

Completion Date

December 5, 2026

Last Updated

January 15, 2026

Enrollment

ACTUAL participants

Conditions

Pancreatic CancerPancreatic CarcinomaPancreatic Ductal AdenocarcinomaPancreatic Cancer MetastaticMetastatic Pancreatic CancerMetastatic Pancreatic Ductal Adenocarcinoma

Interventions

Glipizide

DRUG

Measuring the Effects of Talazoparib in Patients With Advanced Cancer and DNA Repair Variations

NCT04550494

Anatomic Stage III Breast Cancer AJCC v8Anatomic Stage IV Breast Cancer AJCC v8+29 more

View study

RECRUITINGPHASE1/PHASE2

Testing A New Anti-cancer Drug Combination, Entinostat and ZEN003694, for Advanced and Refractory Solid Tumors

NCT05053971

Advanced Malignant Solid NeoplasmLocally Advanced Pancreatic Carcinoma+7 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: January 15, 2026Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

A Study of Glipizide to Treat High Blood Sugar in People With Pancreatic Cancer

Inclusion Criteria

Exclusion Criteria

Measuring the Effects of Talazoparib in Patients With Advanced Cancer and DNA Repair Variations

Testing A New Anti-cancer Drug Combination, Entinostat and ZEN003694, for Advanced and Refractory Solid Tumors

A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors

Resilience and Equity in Aging, Cancer, and Health (REACH)

Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors

A Study to Evaluate the Effectiveness and Safety of Setidegrasib, Given With Either mFOLFIRINOX or NALIRIFOX Chemotherapies, in People With Pancreatic Cancer